Compare SPCB & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | FGEN |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | SPCB | FGEN |
|---|---|---|
| Price | $9.35 | $8.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $18.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 92.5K | 26.2K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.84 | ★ 53.38 |
| Revenue | ★ $26,739,000.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $11.12 | ★ $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.14 | $4.85 |
| 52 Week High | $18.95 | $21.94 |
| Indicator | SPCB | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 38.23 |
| Support Level | $9.08 | $7.99 |
| Resistance Level | $9.75 | $9.09 |
| Average True Range (ATR) | 0.49 | 0.37 |
| MACD | 0.11 | 0.10 |
| Stochastic Oscillator | 70.62 | 34.82 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.